PHILADELPHIA – September 21, 2017 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced that ERT Trial Oversight – its centralized, cloud-based clinical trial management solution – has been named a finalist for the 2017 Scrip Best Sponsor-Focused Technological Development in Clinical Trials Award.
A Scrip representative noted, “The 2017 Scrip Awards provide the biopharma industry with an opportunity to acknowledge its highest achievers across the entire value chain, and to recognize both company and individual achievements. We’re pleased to announce ERT as a finalist for its advancements in improving clinical trial efficiencies for sponsors and CROs.”
ERT Trial Oversight integrates trial data from any source to put real-time, actionable data in the hands of sponsors and their CRO partners. This enhanced visibility enables more proactive decisions, minimizes risks and fosters greater collaboration among trial stakeholders. By addressing these critical areas within the clinical development process, ERT helps sponsors and CROs bring new treatments to market faster.
“We’re honored to be named a Scrip Award finalist, and to be part of this distinguished group of organizations being recognized for their innovation, dedication and hard work in advancing drug development,” said James Corrigan, President and CEO of ERT. “This nomination is a reflection of our employees’ unwavering commitment to delivering innovative and practical solutions that our customers can have confidence in as they bring life-changing medical treatments to the patients who need them.”
Award winners will be announced in London on November 29.
For more information on ERT Trial Oversight, visit ert.com/trial-oversight.
###
About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With more than 40 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2014, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs and CROs have relied on ERT solutions in 9,500+ studies spanning three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence. For more information, go to ert.com or follow us on LinkedIn and Twitter.
